CD20 POSITIVE
Clinical trials for CD20 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CD20 POSITIVE trials appear
Sign up with your email to follow new studies for CD20 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Target CAR-T cells tested in fight against tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack two common proteins (CD19 and CD20) found on certain blood cancer cells. The therapy involves collecting a patient's own immune cells, modifying them in a lab to reco…
Matched conditions: CD20 POSITIVE
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing whether two oral medications, venetoclax and acalabrutinib, can help control mantle cell lymphoma that has returned or didn't respond to previous treatments. The trial involves 32 adults who have already tried at least one other therapy. Researchers want to …
Matched conditions: CD20 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphoma: early trial tests powerful drug cocktail
Disease control OngoingThis early-stage study is testing a new combination of drugs for patients with an aggressive type of lymphoma (DLBCL) that has returned or not responded to previous treatment. Researchers are adding a drug called carfilzomib to a standard chemotherapy regimen to see if it's safe,…
Matched conditions: CD20 POSITIVE
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a combination of two drugs, ibrutinib and rituximab, for people with mantle cell lymphoma, a type of blood cancer. It is for two groups: those whose cancer has returned or hasn't responded to prior treatment, and older patients newly diagnosed with the disea…
Matched conditions: CD20 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC